Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1053
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded622    
    Comments [Add]    
    Cited by others 4    

Recommend this journal


Year : 2013  |  Volume : 50  |  Issue : 1  |  Page : 31-40

Management of gastrointestinal stromal tumor: The lmatinib era and beyond

1 Indian Cooperative Oncology Network, 74 Jerbai Wadia Road, Parel East, Mumbai, India
2 Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India

Correspondence Address:
P M Parikh
Indian Cooperative Oncology Network, 74 Jerbai Wadia Road, Parel East, Mumbai
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-509X.112289

Rights and Permissions

The availability of imatinib followed by other tyrosine kinase inhibitors (TKIs) has dramatically altered the outcome of gastrointestinal stromal tumor (GIST). Patients with advanced or poor risk disease can now expect survival measured in years instead of months. An experienced multi disciplinary team (MDT) will be able to personalize therapy to ensure maximum benefit. This review will provide the updated information and finer points regarding state of the art management of GIST with the use of imatinib and other TKIs.


Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer | Privacy Notice
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow